非感染性葡萄膜炎患者从原研英夫利西单抗系统性转换为生物类似药的疗效研究
转换前后葡萄膜炎静止的 incidence rate ratio(IRR)为0.91(95%CI 0.7-1.1;P=0.38),发作事件IRR为1.04(95%CI 0.36-2.98;P=0.95),均无统计学显著差异。结论认为生物类似药与原研英夫利西单抗在慢性非感染性葡萄膜炎治疗中疗效无差异证据。
要点
- 转换后葡萄膜炎静止的IRR为0.91(95%CI 0.7-1.1;P=0.38),无显著差异。
- 转换后发作事件IRR为1.04(95%CI 0.36-2.98;P=0.95),无显著差异。
- 调整眼内手术后静止IRR为0.90(95%CI 0.7-1.1;P=0.37)。
核心结论
- 在慢性非感染性葡萄膜炎患者中,未发现生物类似药与原研英夫利西单抗在疗效上存在差异的证据。
研究设计与样本
- 前后对照研究,纳入2007至2018年挪威中部卫生区域所有使用英夫利西单抗的患者。
- 主要结局为转换前后葡萄膜炎静止情况,患者每1-3个月随访一次, visits按3个月时间段分组,采用泊松回归分析估计静止的IRR。
主要发现
- 患者多数为白人(87%)、女性(92%),65%患有慢性前葡萄膜炎。
- 使用原研药和生物类似药的中位治疗持续时间分别为38个月(范围8-131个月)和15个月(范围5-55个月)。
- 两种药物治疗期间,伴随使用的免疫抑制药物以及局部和口服激素的使用情况相似。
- 转换后葡萄膜炎静止的IRR为0.91(95%CI 0.7-1.1;P=0.38),无统计学显著差异。
- 转换后发作事件的IRR为1.04(95%CI 0.36-2.98;P=0.95),无统计学显著差异;调整眼内手术后的IRR为0.90(95%CI 0.7-1.1;P=0.37)。
临床怎么用
- 对于使用原研英夫利西单抗的慢性非感染性葡萄膜炎患者,转换为生物类似药后疗效未见明显变化,可作为临床转换的参考依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the efficacy of biosimilar infliximab compared to that of the originator infliximab for the treatment of chronic non-infectious uveitis. DESIGN: Before-and-after study. METHODS: All patients in the Central Norway Health Region between 2007 and 2018 were included. They were switched from originator to biosimilar infliximab therapy from 2014 to 2017. The primary outcome was quiescence of uveitis before and after the switch. All patients were seen every 1-3 months. Visits were binned into 3-month long periods for each patient takingboth medications. Poisson regression analysis was used to estimate the incidence rate ratio (IRR) of quiescence between the 2 treatments. RESULTS: Twenty-nine patients were treated with infliximab. Twenty-three of those patients were switched from originator to biosimilar infliximab. The majority were white (87%), female (92%), and had chronic anterior uveitis (65%). For patients taking the originator and biosimilar drugs, the median treatment duration was38 months (range: 8-131 months) and 15 months (range: 5-55 months), respectively. Concomitant immunosuppressive medications and topical and oral steroids were used similarly during treatment with both originator and biosimilar infliximab. The IRR for quiescence was 0.91 (95% confidence intervals [CI]: 0.7-1.1; P = 0.38), which indicated no statistically significant differences in achieving quiescence after the switch. Also, there were no differences in the incidence rate of flare events with the switch (IRR: 1.04; 95% CI: 0.36-2.98; P = 0.95). IRR adjusted for intraocular surgery was 0.90 (95% CI: 0.7-1.1; P = 0.37). CONCLUSIONS: No evidence of differences in effectiveness were found in comparing biosimilar to originator infliximab in patients with chronic non-infectious uveitis.
引用
- Kumar N, Follestad T, Sen HN, et al. A Systematic Switch From Originator Infliximab to Biosimilar Infliximab in Patients With Non-Infectious Uveitis. Am J Ophthalmol. 2020. PMID: 33121931. doi:10.1016/j.ajo.2020.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。